Cannabinoid Biotech Stocks Higher After Morgan Stanley Earlier Said the U.S. DEA Is Expected This Week To Reclassify GW Pharma's CBD Epidiolex For Medicinal Use; GW Pharma Shares Up 5.8%, Peer Zynerba Pharma Shares Up 5.1%